Abeona Therapeutics Inc (ABEO) - News Archive

Gene Therapy Advancement for X-Linked Retinoschisis: A Closer Look at ABO-503 and the FDA s RDEA Pilot Program X-Linked Retinoschisis (XLRS) is a debilitating genetic condition primarily affecting males, manifesting as...

for CSIMarket.com The recent approval of ZEVASKYN (prademagene zamikeracel) by the U.S. Food and Drug Administration (FDA) marks a significant advancement in the treatment of Recessive Dystrophic Epidermolysis Bullosa (...

Abeona Therapeutics’ Strategic Equity Awards: A Move to Bolster Innovation and Investor ConfidenceCLEVELAND, Feb. 3, 2025 In a significant move to attract and retain top talent, Abeona Therapeutics Inc. (Nasdaq: ABEO) h...

Strategic Equity Allocations: Abeona Therapeutics Journey of Empowering Innovation and Its Impact on Shareholder ValueIn a fiscal landscape defined by relentless competition and rapid innovation, Abeona Therapeutics Inc...

In the fast-evolving sphere of biopharmaceuticals, maintaining a competitive edge is crucial, especially for companies like Abeona Therapeutics Inc. (Nasdaq: ABEO), which is devoted to developing groundbreaking gene the...

Abeona Therapeutics Faces Financial Headwinds While Pursuing Gene Therapy Approval: A Close Look at Recent Developments and Employee InducementsAbeona Therapeutics Inc. (Nasdaq: ABEO), a clinical-stage biopharmaceutical...

Abeona Therapeutics: Navigating Financial Turbulence in the Quest for Gene Therapy ApprovalCLEVELAND — In the high-stakes world of biotech, few situations are as precarious as the race for the next groundbreaking treatm...

Equity Awards Granted to New Employees at Abeona Therapeutics Under Nasdaq Listing Rule 5635(c)(4) CSIMarket.com Abeona Therapeutics Inc. (Nasdaq: ABEO), a pioneering company in the realm of gene and cell therapy, has a...

This article provides an in-depth analysis of the partnership between Abeona Therapeutics Inc. and Beacon Therapeutics, focusing on the evaluation of Abeona s patented AAV204 capsid for the development and commercializa...

Abeona Therapeutics Inc. has recently announced the issuance of equity awards to new non-executive employees who have joined the company. This move comes in compliance with Nasdaq Listing Rule 5635(c)(4) and reflects Ab...

In a recent press release, Abeona Therapeutics Inc. (Nasdaq: ABEO) announced the successful pricing of an underwritten offering of common stock and pre-funded warrants, raising $75 million. This article will outline the...

Abeona Therapeutics Inc., a leading biopharmaceutical company, has recently announced the granting of equity awards to new non-executive employees joining the organization. These awards have been approved in accordance...

Abeona Therapeutics Grants Employee Inducement Awards - Impact on Company SharesAbeona Therapeutics, a leading biopharmaceutical company, has recently announced the allocation of equity awards to new non-executive emplo...

Abeona Therapeutics Secures $50 Million Credit Facility to Accelerate GrowthCLEVELAND, Jan. 08, 2024 - Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading biopharmaceutical company focused on developing transformative ge...

On December 15th, 2023, Abeona Therapeutics Inc. (Nasdaq: ABEO) announced its recent grant of equity awards to new non-executive employees, in compliance with Nasdaq Listing Rule 5635(c)(4). These inducement grants aim...